153
Participants
Start Date
May 20, 2021
Primary Completion Date
February 9, 2022
Study Completion Date
February 9, 2022
LY3556050
Administered orally
Placebo
Administered orally
Altoona Center For Clinical Research, Duncansville
Clinical Research Center of Reading,LLC, Wyomissing
Synexus Clinical Research US, Inc - Orlando, The Villages
Synexus Clinical Research US, Inc - Orlando, Orlando
Clinical Research of South Florida, Coral Gables
Suncoast Research Group, Miami
University of Miami Don Suffer Clinical Research Building, Miami
New Horizon Research Center, Miami
VIN-Julie Schwartzbard, Aventura
Martin E. Hale M.D., P.A., Plantation
Synexus Clinical Research - St. Petersburg, Pinellas Park
Renstar Medical Research, Ocala
Simon Williamson Clinic, Birmingham
Synexus - Cincinnati, Cincinnati
META Medical Research Institute, Dayton
Great Lakes Research Group, Inc., Bay City
Synexus Clinical Research, Chicago
Northwestern University, Chicago
StudyMetrix Research, City of Saint Peters
Cedar Health Research, Dallas
Synexus - US, San Antonio
Synexus- Chandler, Chandler
Alliance for Multispecialty Research - Clinical Research Consortium, Tempe
Synexus Clinical Research - Glendale, Glendale
Artemis Institute for Clinical Research, San Diego
Artemis Institute for Clinical Research, Riverside
Irvine Clinical Research Center, Irvine
Northwest Clinical Research Center, Bellevue
Rainier Clinical Research Center, Renton
CMR of Greater New Haven, Hamden
Boston Clinical Trials, Boston
ActivMed Practices and Research, Methuen
MedVadis Research Corporation, Waltham
Ponce Medical School Foundation Inc., Ponce
Latin Clinical Trial Center, San Juan
Eli Lilly and Company
INDUSTRY